{"title":"Development and validation of a predictive model for acute exacerbation in chronic obstructive pulmonary disease patients with comorbid insomnia.","authors":"Qianqian Gao, Hongbin Zhu","doi":"10.3389/fmed.2025.1511874","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To develop and validate a risk prediction model for estimating the likelihood of insomnia in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).</p><p><strong>Methods: </strong>This prospective study enrolled 253 patients with AECOPD treated at the Department of Respiratory and Critical Care Medicine, Chaohu Hospital Affiliated with Anhui Medical University, between September 2022 and April 2024. Patients were randomly assigned to a training set and a testing set in a 7:3 ratio. Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis was conducted in the training set to identify factors associated with insomnia in patients with AECOPD. A nomogram was constructed based on four identified variables to visualize the prediction model. Model validation involved the Hosmer-Lemeshow test, and its performance was assessed through receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Model interpretability was further enhanced using SHapley Additive exPlanations (SHAP).</p><p><strong>Results: </strong>PSQI grade, marital status (widowed), white blood cell (WBC) count, and eosinophil percentage (EOS%) were identified as significant predictors of insomnia in patients with AECOPD. The nomogram based on these predictors exhibited excellent predictive performance, with areas under the ROC curve (AUCs) of 0.987 and 0.933 for the training and testing sets, respectively. The calibration curves and Hosmer-Lemeshow test demonstrated strong agreement between predicted and observed outcomes, while DCA confirmed the model's superior clinical utility.</p><p><strong>Conclusion: </strong>This study established a risk prediction model based on four variables to estimate the probability of insomnia in patients with AECOPD. The model exhibited excellent predictive accuracy and clinical applicability, offering valuable guidance for early identification and management of insomnia in this population.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1511874"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968377/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1511874","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To develop and validate a risk prediction model for estimating the likelihood of insomnia in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Methods: This prospective study enrolled 253 patients with AECOPD treated at the Department of Respiratory and Critical Care Medicine, Chaohu Hospital Affiliated with Anhui Medical University, between September 2022 and April 2024. Patients were randomly assigned to a training set and a testing set in a 7:3 ratio. Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis was conducted in the training set to identify factors associated with insomnia in patients with AECOPD. A nomogram was constructed based on four identified variables to visualize the prediction model. Model validation involved the Hosmer-Lemeshow test, and its performance was assessed through receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Model interpretability was further enhanced using SHapley Additive exPlanations (SHAP).
Results: PSQI grade, marital status (widowed), white blood cell (WBC) count, and eosinophil percentage (EOS%) were identified as significant predictors of insomnia in patients with AECOPD. The nomogram based on these predictors exhibited excellent predictive performance, with areas under the ROC curve (AUCs) of 0.987 and 0.933 for the training and testing sets, respectively. The calibration curves and Hosmer-Lemeshow test demonstrated strong agreement between predicted and observed outcomes, while DCA confirmed the model's superior clinical utility.
Conclusion: This study established a risk prediction model based on four variables to estimate the probability of insomnia in patients with AECOPD. The model exhibited excellent predictive accuracy and clinical applicability, offering valuable guidance for early identification and management of insomnia in this population.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world